Bubble trouble: Anaphylactic shock, threatened myocardial infarction, and transient renal failure after intravenous echo contrast for left ventricular cavity opacification preceding dobutamine stress echo

European Journal of Echocardiography

Volumn 10, Issue 5, 2009, Pages 707-710

  Ionescu, Adrian ^a  

^a MORRISTON HOSPITAL   (United Kingdom)

Author keywords

Anaphylactic shock; Dobutamine stress echo; Sonovue

Indexed keywords

CREATININE; DOBUTAMINE; SONOVUE; TROPONIN T;

ADULT; ANAPHYLACTIC SHOCK; ARTICLE; CASE REPORT; DISEASE COURSE; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; HEART INFARCTION; HEART LEFT VENTRICLE; HUMAN; HYPOTENSION; KIDNEY FAILURE; MALE; PARESTHESIA; PRIORITY JOURNAL; SINUS BRADYCARDIA; STRESS ECHOCARDIOGRAPHY;

ANAPHYLAXIS; CONTRAST MEDIA; ECHOCARDIOGRAPHY, STRESS; ELECTROCARDIOGRAPHY; HUMANS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHOLIPIDS; SULFUR HEXAFLUORIDE;

EID: 67650885509     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1093/ejechocard/jep073     Document Type: Article

References (15)

1. http://www.fda.gov/cder/drug/infopage/microbubble/default.htm accessed online 19 January 2009.
2. The European Agency for the Evaluation of Medicinal Products. Public statement on Sonovue. New contraindication in patients with heart disease. Restriction of use to non-cardiac imaging. London, 19 May 2004, EMEA/CMPM/212/04.
3. Main ML, Goldman JH, Grayburn PA. Thinking outside the 'box'-the ultrasound contrast controversy. J Am Coll Cardiol 2007;50:2434-7.
4. Grayburn PA. 'Product safety' compromises patient safety (an unjustified black box warning on ultrasound contrast agents by the Food and Drug Administration). Am J Cardiol 2008;101:892-3.
5. Van Camp G, Droogmans S, Cosyns B. Bio-effects of contrast ultrasound agents in daily clinical practice: fact or fiction? Eur Heart J 2007;28: 1190-2.
6. Lindner JL, Wei K. Action or over-reaction? J Am Coll Cardiol 2008; 1: 109-10.
7. Dijkmans PA, Visser CA, Kamp O. Adverse reactions to ultrasound contrast agents: is the risk worth the benefit? Eur J Echocardiogr 2005;6:363-6.
8. Dolan MS, Gala SS, Dodla S et al. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiogra- phy. J Am Coll Cardiol 2009;53:32-8.
9. Main ML, Ryan AC, Davis TE, Albano MP, Kusnetzky LL, Hibberd M. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol 2008;102:1742-6.
10. Timperley J, Mitchell ARJ, Thibault H, Mirza IH, Becher H. Safety of contrast Dobutamine stress echocardiography: a single center experience. J Am Soc Echocardiogr 2005;18:163-7.
11. Calvo D, de la Hera JM, Lee D.-H. Contrast echocardiography and clinical safety. Rev Esp Cardiol 2006;59:397-401.
12. de Groot MC, van Zwieten-Boot BJ, van Grootheest AC. Severe adverse reactions after the use of sulphur hexafluoride (SonoVue) as an ultrasonographic agent. Ned Tijdschr Geneeskd 2004;148:1887-8.
13. Galema TW, Geleijnse ML, Vletter WB, de Laat L, Michels M, ten Cate FJ. Clinical usefulness of SonoVue contrast echocardiography: the Thorax- centre experience. Neth Heart J 2007;15:55-60.
14. Geleijnse ML, Nemes A, Vletter WB, Michels M, Soliman O II, Caliskan K et al. Adverse reactions after the use of sulphur hexafluoride (SonoVue) echo contrast agent. J Cardiovasc Med 2009;10:75-7.
15. Mulvagh SL, Vannan M, Abdelmoneim SS et al. ASE consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr 2008;20:1179-1201.